ArticleCureus2025
Heart Failure With Preserved Ejection Fraction and Low B-type Natriuretic Peptide: A Diagnostic Dilemma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Natriuretic Peptides to microRNAs: Multi-Analyte Liquid Biopsy Horizons in Heart Failure.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is referred to as a clinical syndrome caused by an abnormality in the cardiac function/structure of the heart, leading to pulmonary or systemic vascular congestion. B-type natriuretic peptide (BNP) is particularly useful for ruling out heart failure when levels are low due to its high negative predictive value. On the other hand, BNP has reduced specificity for heart failure with preserved ejection fraction (HFpEF) due to increased clearance and enhanced degradation of natriuretic peptides (NP) which contribute to lower BNP levels. In patients with HFpEF, reduced myocardial wall stress is associated with low BNP, as compared to heart failure with reduced ejection fraction (HFrEF). BNP and N-terminal pro-BNP (NT-proBNP) levels may be in the normal range in chronically treated heart failure patients, especially if younger than 75 years. BNP levels can be lower in HFpEF due to factors like obesity and atrial function. NT-proBNP levels vary by ethnicity, with African American patients exhibiting lower levels, potentially linked to salt-sensitive hypertension and left ventricular hypertrophy. In our case report, the patient presented with classic signs and symptoms of HFpEF exacerbation but had a BNP level that was inconsistent with HF. This signifies the importance of over-reliance on BNP in patients with HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.